Literature DB >> 35499788

Comment on: "Impact of Tumor Size on the Outcomes of Patients with Resectable Distal Pancreatic Cancer".

D Brock Hewitt1, Hassan Aziz1, Timothy M Pawlik2.   

Abstract

Entities:  

Year:  2022        PMID： 35499788     DOI： 10.1245/s10434-022-11840-6

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN： 1068-9265            Impact factor:   5.344


× No keyword cloud information.
  7 in total

1.  Validation of the American Joint Commission on Cancer (AJCC) 8th Edition Staging System for Patients with Pancreatic Adenocarcinoma: A Surveillance, Epidemiology and End Results (SEER) Analysis.

Authors:  Sivesh K Kamarajah; William R Burns; Timothy L Frankel; Clifford S Cho; Hari Nathan
Journal:  Ann Surg Oncol       Date:  2017-02-17       Impact factor: 5.344

2.  Impact of Tumor Size on the Outcomes of Patients with Resectable Distal Pancreatic Cancer: Lessons Learned from a Series of 158 Radical Resections.

Authors:  Genki Watanabe; Yuta Ushida; Atsushi Oba; Yoshihiro Ono; Takafumi Sato; Yosuke Inoue; Yu Takahashi; Akio Saiura; Hiromichi Ito
Journal:  Ann Surg Oncol       Date:  2021-08-17       Impact factor: 5.344

3.  Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma.

Authors:  Chandrajit P Raut; Jennifer F Tseng; Charlotte C Sun; Huamin Wang; Robert A Wolff; Christopher H Crane; Rosa Hwang; Jean-Nicolas Vauthey; Eddie K Abdalla; Jeffrey E Lee; Peter W T Pisters; Douglas B Evans
Journal:  Ann Surg       Date:  2007-07       Impact factor: 12.969

4.  EMT and dissemination precede pancreatic tumor formation.

Authors:  Andrew D Rhim; Emily T Mirek; Nicole M Aiello; Anirban Maitra; Jennifer M Bailey; Florencia McAllister; Maximilian Reichert; Gregory L Beatty; Anil K Rustgi; Robert H Vonderheide; Steven D Leach; Ben Z Stanger
Journal:  Cell       Date:  2012-01-20       Impact factor: 41.582

5.  Comparative genomic analysis of head and body/tail of pancreatic ductal adenocarcinoma at early and late stages.

Authors:  Xueyou Zhang; Shi Feng; Qian Wang; Haitao Huang; Ruihan Chen; Qinfen Xie; Wu Zhang; Aodi Wang; Shuirong Zhang; Lingjian Wang; Ming Yao; Qi Ling
Journal:  J Cell Mol Med       Date:  2021-01-16       Impact factor: 5.310

6.  Surgical Outcome Results From SWOG S1505: A Randomized Clinical Trial of mFOLFIRINOX Versus Gemcitabine/Nab-paclitaxel for Perioperative Treatment of Resectable Pancreatic Ductal Adenocarcinoma.

Authors:  Syed A Ahmad; Mai Duong; Davendra P S Sohal; Namita S Gandhi; Muhammad Shaalan Beg; Andrea Wang-Gillam; James L Wade; Elena Gabriela Chiorean; Katherine A Guthrie; Andrew M Lowy; Philip A Philip; Howard S Hochster
Journal:  Ann Surg       Date:  2020-09-01       Impact factor: 13.787

7.  Defining the molecular pathology of pancreatic body and tail adenocarcinoma.

Authors:  S B Dreyer; N B Jamieson; R Upstill-Goddard; P J Bailey; C J McKay; A V Biankin; D K Chang
Journal:  Br J Surg       Date:  2018-01       Impact factor: 6.939
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.